Puma Biotechnology | PBYI - Current Liabilities

Stock Price
6.62
Daily Change
0.01 0.12%
Monthly
5.38%
Yearly
137.20%
Q1 Forecast
5.65

Puma Biotechnology reported $82.73M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Agios Pharmaceuticals USD 74.76M 4.35M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Amgen USD 25.49B 3.7B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
Exelixis USD 405.64M 31.86M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Glaxosmithkline GBP 28.68B 8.3B Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
MacroGenics USD 44.47M 5.47M Sep/2025
Moderna USD 1.68B 109M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Takeda JPY 2.61T 470.53B Dec/2025
TG Therapeutics USD 156.81M 15.08M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vanda Pharmaceuticals USD 117.87M 3.62M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025